We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Next-Generation Sequencing (NGS) Market Driven by Launch of Technologically Advanced Systems

By LabMedica International staff writers
Posted on 10 Feb 2023

Next generation sequencing (NGS) is a massively parallel sequencing technology that offers scalability, ultra-high throughput, and high speed to determine the order of nucleotides in the entire genome. More...

DNA pre-sequencing is among the most significant steps in the overall sequencing protocol as it involves preparation of sample for the subsequent sequencing reaction. NGS is being gradually integrated into clinical laboratory analysis, testing, and diseases diagnostics in healthcare sectors across the world. The global NGS market is projected to grow at a CAGR of 15.7% from USD 13 billion in 2022 to USD 27 billion by 2027, driven by the launch of technologically advanced NGS systems and improving regulatory and reimbursement scenarios for NGS-based diagnostic tests. However, the end-user budget constraints in developing countries are expected to restrain market growth.

These are the latest findings of MarketsandMarkets (Northbrook, IL, USA), a growth consulting and program management firm.

Based on product & service, the consumables segment dominated the global NGS market in 2021 with the largest share due to the launch of new NGS consumables and demand for reagents and kits. Based on technology, the sequencing by synthesis segment accounted for the largest share of the global NGS market in 2021 due to the launch of new NGS platforms based on sequencing by synthesis technology. Based on application, the diagnostics segment accounted for the largest share of the global NGS market in 2021 due to the increasing demand for NGS based diagnostic products for cancer and noninvasive prenatal testing (NIPT).

Based on end users, the academic institutes & research centers segment dominated the global NGS market in 2021 with the largest share due to a growing number of collaborations between NGS market players and academic & research institutes. Geographically, North America accounted for the largest share of the global NGS market in 2021, driven by the increasing demand for new NGS based diagnostic tools, availability of research funding, and presence of prominent market players in the region.

Related Links:
MarketsandMarkets


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.